RxDoctor Payments Data

Jong Moon, MD

General Practice · Shafter, CANPI 1760545925

Payments from drug & device makers

$997in general payments, 2019–2025

Across 57 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$286
  • Lilly USA, LLC$226
  • Novo Nordisk$183
  • Boehringer Ingelheim$104
  • Pfizer$39
  • AbbVie$32
  • plus $128 from 7 others

What the payments were for

  • Food & beverage$997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$997 in reported general payments places this provider in the 80th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$2,860
Medicare patients
106
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$97,908
EliquisApixaban74$75,560
JanuviaSitagliptin Phosphate57$55,060
TradjentaLinagliptin35$30,180
EntrestoSacubitril/Valsartan11$13,618
FarxigaDapagliflozin Propanediol12$11,930
LinzessLinaclotide19$11,085
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$7,637
Celecoxib77$3,953
Atorvastatin Calcium438$3,649
Diclofenac Sodium202$3,383
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,190
Omega-3 Acid Ethyl Esters89$2,892
FenofibrateFenofibrate,micronized114$2,691
Albuterol Sulfate HfaAlbuterol Sulfate84$2,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$104$128,088134 claims
PfizerEliquis$39$75,56074 claims
MerckJanuvia$18$55,06057 claims
NovartisEntresto$27$13,61811 claims
AstraZenecaFarxiga$286$11,93012 claims
AbbVieLinzess$32$11,08519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 12,963 general practice providers in California.

Other general practice in Shafter

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →